[go: up one dir, main page]

NO20071300L - Trifluormetylsubstituerte benzamider som kinaseinhibitorer. - Google Patents

Trifluormetylsubstituerte benzamider som kinaseinhibitorer.

Info

Publication number
NO20071300L
NO20071300L NO20071300A NO20071300A NO20071300L NO 20071300 L NO20071300 L NO 20071300L NO 20071300 A NO20071300 A NO 20071300A NO 20071300 A NO20071300 A NO 20071300A NO 20071300 L NO20071300 L NO 20071300L
Authority
NO
Norway
Prior art keywords
compounds
trifluoromethyl
treatment
kinase inhibitors
substituted benzamides
Prior art date
Application number
NO20071300A
Other languages
English (en)
Inventor
Giorgio Caravatti
Pascal Furet
Lawrence Blas Perez
Patricia Imbach
Georg Martiny Baron
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20071300L publication Critical patent/NO20071300L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører trifluormetyl-substituerte bensamid-forbindelser med formelen I, farmasøytiske preparater omfattende disse forbindelser, deres anvendelse som eller for fremstilling av farmasøytiske preparater, særlig som inhibitorer av protein-kinaser og/eller behandling av en tilstand, forstyrrelse eller sykdomstilstand som betinges av en protein-kinase-aktivitet og/eller en proliferativ sykdom, metoder for behandling omfattende administering av forbindelsene, spesielt for terapeutisk og profylaktisk behandling, metoder for fremstilling av forbindelsene og nye mellomprodukter og delvis trinn for deres syntese.
NO20071300A 2004-08-11 2007-03-09 Trifluormetylsubstituerte benzamider som kinaseinhibitorer. NO20071300L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds
PCT/EP2005/008695 WO2006015859A1 (en) 2004-08-11 2005-08-10 Trifluoromethyl substituted benzamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20071300L true NO20071300L (no) 2007-04-19

Family

ID=33017336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071300A NO20071300L (no) 2004-08-11 2007-03-09 Trifluormetylsubstituerte benzamider som kinaseinhibitorer.

Country Status (17)

Country Link
US (2) US20060035897A1 (no)
EP (1) EP1778640A1 (no)
JP (1) JP2008509187A (no)
KR (1) KR20070046851A (no)
CN (2) CN101696188A (no)
AU (1) AU2005270313A1 (no)
BR (1) BRPI0514288A (no)
CA (1) CA2575316A1 (no)
EC (1) ECSP077235A (no)
GB (1) GB0417905D0 (no)
IL (1) IL181169A0 (no)
MA (1) MA28822B1 (no)
MX (1) MX2007001642A (no)
NO (1) NO20071300L (no)
RU (1) RU2007108861A (no)
TN (1) TNSN07048A1 (no)
WO (1) WO2006015859A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
JP5079500B2 (ja) * 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
AU2007234382B2 (en) * 2006-04-05 2011-06-09 Novartis Ag Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
BRPI0714307A2 (pt) * 2006-07-13 2014-06-10 Novartis Ag Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
DE602007013079D1 (de) * 2006-09-05 2011-04-21 Amgen Inc Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren
US20100173426A1 (en) * 2006-12-19 2010-07-08 Johnson Faye M Biomaker identifying the reactivation of stat3 after src inhibition
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
US7846944B2 (en) * 2007-05-07 2010-12-07 Amgen Inc. Pyrazolo-pyridinone compounds and methods of use thereof
US8022085B2 (en) * 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
WO2009036275A1 (en) * 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
WO2009117156A1 (en) * 2008-03-21 2009-09-24 Amgen Inc. Pyrazolo-pyrazinone compounds and methods of use thereof
KR20100134693A (ko) 2008-04-23 2010-12-23 교와 핫꼬 기린 가부시키가이샤 2-아미노퀴나졸린 유도체
US8455495B2 (en) 2008-08-29 2013-06-04 Amgen Inc. Pyridazino-pyridinone compounds and methods of use
US8420649B2 (en) 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
WO2010042649A2 (en) 2008-10-10 2010-04-15 Amgen Inc. PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
WO2010042646A1 (en) 2008-10-10 2010-04-15 Amgen Inc. Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
KR101457027B1 (ko) 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
AU2010313152A1 (en) * 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
EP2701507A1 (en) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
MY199989A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
BRPI0514288A (pt) 2008-06-10
MX2007001642A (es) 2007-04-10
GB0417905D0 (en) 2004-09-15
ECSP077235A (es) 2007-03-29
TNSN07048A1 (en) 2008-06-02
AU2005270313A1 (en) 2006-02-16
RU2007108861A (ru) 2008-09-20
KR20070046851A (ko) 2007-05-03
IL181169A0 (en) 2007-07-04
US20060035897A1 (en) 2006-02-16
WO2006015859A1 (en) 2006-02-16
US20080096883A1 (en) 2008-04-24
JP2008509187A (ja) 2008-03-27
CN101696188A (zh) 2010-04-21
MA28822B1 (fr) 2007-08-01
EP1778640A1 (en) 2007-05-02
CN101039914A (zh) 2007-09-19
CA2575316A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20071300L (no) Trifluormetylsubstituerte benzamider som kinaseinhibitorer.
NO20071875L (no) Bicykliske amider som kinaseinhibitorer
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
TW200621783A (en) 1,4 substituted pyrazolopyrimidines as kinase inhibitors
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
MX2022013615A (es) Inhibidores de macrociclo de peptidilarginina deiminasas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application